Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory sarcomas.

Trial Details

NCT ID

NCT06156410

Phase

PHASE1

Sponsor

Children's Hospital of Philadelphia

Status

RECRUITING

Cancer Type

Osteosarcoma Sarcoma

Interventions

Cabozantinib

Locations (sample)

San Francisco, California, United States|37.77493,-122.41942
Aurora, Colorado, United States|39.72943,-104.83192
Philadelphia, Pennsylvania, United States|39.95238,-75.16362
Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

Histologic diagnosis of any sarcoma, including bone and soft tissue sarcomas. Biopsy from current relapse/progression is highly preferred, though w…
Disease that has progressed on or relapsed after upfront initial therapy, which must have included traditional chemotherapy.
Evaluable or Measurable disease, according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1), within 21 days of enrollment.
Age, within the following parameters by cohort:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →